Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (101-110 of 205) with videos related to

Pageof 21
Sort By:
PET Clinics|January 10, 2024
PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract CancersJorge D Oldan, Jennifer A Schroeder, Jean Hoffman-Censits, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinomaStephen A Boorjian, Matthew I Milowsky, Jodi Kaplan, et al.
European Urology|September 3, 2024
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncologySandy Figiel, Anthony Bates, David A Braun, et al.
The Journal of Urology|July 28, 2020
Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle Invasive Bladder CancerChelsea K Osterman, Allison M Deal, Hannah McCloskey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancerArjun V Balar, Andrea B Apolo, Irina Ostrovnaya, et al.
BJU International|August 17, 2010
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implicationsSatish K Tickoo, Matthew I Milowsky, Nitin Dhar, et al.
JCO Precision Oncology|July 6, 2023
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsDeborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, et al.
Journal of Pain and Symptom Management|March 2, 2021
Pre-Post Evaluation of Collaborative Oncology Palliative Care for Patients With Stage IV CancerLaura C Hanson, Kathryn L Wessell, Jenny Hanspal, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2014
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biologyJeffrey S Damrauer, Katherine A Hoadley, David D Chism, et al.
Cancer|January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
Pageof 21

Showing results (101-110 of 205) with videos related to

Sort By:
Pageof 21
PET Clinics|January 10, 2024
PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract CancersJorge D Oldan, Jennifer A Schroeder, Jean Hoffman-Censits, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinomaStephen A Boorjian, Matthew I Milowsky, Jodi Kaplan, et al.
European Urology|September 3, 2024
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncologySandy Figiel, Anthony Bates, David A Braun, et al.
The Journal of Urology|July 28, 2020
Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle Invasive Bladder CancerChelsea K Osterman, Allison M Deal, Hannah McCloskey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancerArjun V Balar, Andrea B Apolo, Irina Ostrovnaya, et al.
BJU International|August 17, 2010
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implicationsSatish K Tickoo, Matthew I Milowsky, Nitin Dhar, et al.
JCO Precision Oncology|July 6, 2023
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsDeborah B Doroshow, Peter H O'Donnell, Jean H Hoffman-Censits, et al.
Journal of Pain and Symptom Management|March 2, 2021
Pre-Post Evaluation of Collaborative Oncology Palliative Care for Patients With Stage IV CancerLaura C Hanson, Kathryn L Wessell, Jenny Hanspal, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2014
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biologyJeffrey S Damrauer, Katherine A Hoadley, David D Chism, et al.
Cancer|January 5, 2024
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Tracy L Rose, Benjamin L Maughan, et al.
Pageof 21